NextCure Reports Third-Quarter 2026 Financial Results and Business Update
NextCure reported results for the quarter ended September 30, 2026, and said it continues to advance its proposed merger with Avere Therapeutics.
Story updates
09:07:31 PM UTC
SquawkNews
Financing commitments for NextCure’s proposed merger with Avere increased to approximately $820M, including a previously announced $320M private placement and an additional $500M private placement. The merger remains subject to stockholder approval and other customary closing conditions.Material De…
BALTIMORE, Md., Nov. 10, 2026 (GLOBE NEWSWIRE) -- NextCure, Inc. NASDAQ:NXTC, today provided a business update and reported financial results for the third quarter ended September 30, 2026.The Company continues to advance its proposed merger (the “Merger”) with Avere Therapeutics, Inc., a privately…